Raymond James Financial
BCLI

Raymond James Financial’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Raymond James Financial’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,158
Closed -$5.78K – 5136
2025
Q2 		$5.78K Buy
+5,158
New +$5.77K ﹤0.01% 6127

Other funds holding BCLI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.53B AUM 17.43% 1-Year Est. Return

Raymond James Financial's BCLI Position: Q3 2025 in Review

Raymond James Financial sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 5,158 shares — an estimated $5.78K sold.

Raymond James Financial first reported a position in BCLI in Q2 2025 and held it in 1 quarter. The position peaked at $5.78K in Q2 2025. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • Raymond James Financial reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 5,158 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $5.78K.
  • Raymond James Financial first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's BRAINSTORM CELL THERAPUTC position peaked at $5.78K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.